1. Home
  2. AMR vs MLYS Comparison

AMR vs MLYS Comparison

Compare AMR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Metallurgical Resources Inc.

AMR

Alpha Metallurgical Resources Inc.

HOLD

Current Price

$243.22

Market Cap

2.6B

Sector

Energy

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$32.32

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMR
MLYS
Founded
2016
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
AMR
MLYS
Price
$243.22
$32.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$168.00
$47.33
AVG Volume (30 Days)
249.8K
1.5M
Earning Date
02-27-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,226,356,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$97.41
$8.24
52 Week High
$253.82
$47.65

Technical Indicators

Market Signals
Indicator
AMR
MLYS
Relative Strength Index (RSI) 68.87 33.20
Support Level $230.99 $31.67
Resistance Level $253.82 $33.64
Average True Range (ATR) 12.37 1.67
MACD 2.22 -0.23
Stochastic Oscillator 78.46 19.56

Price Performance

Historical Comparison
AMR
MLYS

About AMR Alpha Metallurgical Resources Inc.

Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: